Objective To investigate the clinical efficacy of liver-protecting tablets in preventing statins-induced liver injury. Methods 260 cases of elderly patients with normal liver function and clinical indications of statins were divided into the observation group and the control group, each of 130 cases. Patients in the control group were routinely treated with atorvastatin while the patients in the observation group added liver-protecting tablets on the basis of routine treatment, then the damage of liver function between two groups after 1 month and 3 months were compared. Results There was no statistically significant difference in the baseline and serum lipid level between two groups. Both groups of blood lipid levels were significantly lower after treatment, and there was no statistically significant difference between two groups. The incidence rate in the observation group of mild liver function damage after 1 month and all the liver function injury event in total 3 months were lower than the control group, the difference had statistical significance(P<0.05). Conclusion The treatment effect of elderly patients with atorvastatin is significant, and the total incidence rate of liver function injury is low. Hugan tablets can reduce the occurrence of mild liver function injury to a certain degree, and it does not reduce the clinical efficacy of atorvastatin.%目的 探讨护肝片预防他汀类药物性肝损的临床疗效.方法 选取肝功能正常且临床有他汀类药物适应证的老年患者260例,随机分为观察组与对照组,各130例.对照组患者常规服用阿托伐他汀药物治疗,观察组在对照组基础上加用护肝片治疗,比较两组服药后1、3个月肝功能损害发生率情况.结果 两组患者基础情况及血脂水平差异无统计学意义,治疗后血脂水平均较治疗前明显下降,两组间差异无统计学意义.观察组服药1个月后轻度肝功能损害发生率及3个月内总肝功能损害发生率均低于对照组,差异有统计学意义(P<0.05).结论 老年患者使用阿托伐他汀治疗效果显著,药物性肝功能损害总体发生率较低,护肝片可一定程度减少轻度药物性肝功能损害事件发生,且护肝片不影响阿托伐他汀钙片的临床疗效.
展开▼
